Fig. 2From: Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institutionIgG geometric mean concentrations on TP0, TP1 and TP2 in each cohort, AU/mL. TP0 is day of 1st dose, TP1 is day of 2nd dose (3rd week after 1st dose), TP3 is 5th week after 1st doseBack to article page